Antimicrobial Susceptibility of Mycobacterium abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital

References

• Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis. 1993;147:1271–1278. doi:10.1164/ajrccm/147.5.12718484642
   PubMed Web of Science ®Google Scholar
• Lee MR, et al. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis. 2015;21:1638–1646. doi:10.3201/2109.14163426295364
   PubMed Web of Science ®Google Scholar
• Leao SC, Tortoli E, Euzeby JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol. 2011;61:2311–2313. doi:10.1099/ijs.0.023770-021037035
   PubMed Web of Science ®Google Scholar
• Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011;52:565–571. doi:10.1093/cid/ciq23721292659
   PubMed Web of Science ®Google Scholar
• Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016;45:123–134. doi:10.1016/j.ijid.2016.03.00626976549
   PubMed Web of Science ®Google Scholar
• Griffith DE, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. doi:10.1164/rccm.200604-571ST17277290
   PubMed Web of Science ®Google Scholar
• Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother. 2009;53:1367–1376. doi:10.1128/AAC.01275-0819171799
   PubMed Web of Science ®Google Scholar
• Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67:810–818. doi:10.1093/jac/dkr57822290346
   PubMed Web of Science ®Google Scholar
• Richard M, Gutierrez AV, Kremer L. Dissecting erm(41)-mediated macrolide-inducible resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2020;64. doi:10.1128/AAC.01879-19.
   Web of Science ®Google Scholar
• Aziz DB, Go ML, Dick T. Rifabutin suppresses inducible clarithromycin resistance in Mycobacterium abscessus by blocking induction of whiB7 and erm41. Antibiotics. 2020;9. doi:10.3390/antibiotics9020072.
   Web of Science ®Google Scholar
• Wallace RJ Jr. et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40:1676–1681. doi:10.1128/AAC.40.7.16768807061
   PubMed Web of Science ®Google Scholar
• Soroka D, et al. Characterization of broad-spectrum Mycobacterium abscessus class A beta-lactamase. J Antimicrob Chemother. 2014;69:691–696. doi:10.1093/jac/dkt41024132992
   PubMed Web of Science ®Google Scholar
• Lefebvre AL, et al. Inhibition of the beta-Lactamase BlaMab by Avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.02440-16
   Web of Science ®Google Scholar
• Rahme C, Butterfield JM, Nicasio AM, Lodise TP. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Diagn Microbiol Infect Dis. 2014;80:239–259. doi:10.1016/j.diagmicrobio.2014.07.00725308565
   PubMed Web of Science ®Google Scholar
• Soroka D, et al. Inhibition of beta-lactamases of mycobacteria by avibactam and clavulanate. J Antimicrob Chemother. 2017;72:1081–1088. doi:10.1093/jac/dkw54628039278
   PubMed Web of Science ®Google Scholar
• Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and beta-Lactams: emerging insights and potential opportunities. Front Microbiol. 2018;9:2273. doi:10.3389/fmicb.2018.0227330319581
   PubMed Web of Science ®Google Scholar
• Yu XL, et al. Identification and characterization of non-tuberculous mycobacteria isolated from tuberculosis suspects in Southern-central China. PLoS One. 2014;9:e114353. doi:10.1371/journal.pone.011435325463697
   PubMed Web of Science ®Google Scholar
• Macheras E, et al. Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. J Clin Microbiol. 2009;47:2596–2600. doi:10.1128/JCM.00037-0919515839
   PubMed Web of Science ®Google Scholar
• Nie W, Duan H, Huang H, Lu Y, Chu N. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis Mycobacteria Isolates. Biomed Res Int. 2015;506598. doi:10.1155/2015/50659826146620
   PubMed Web of Science ®Google Scholar
• Maurer FP, Ruegger V, Ritter C, Bloemberg GV, Bottger EC. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother. 2012;67:2606–2611. doi:10.1093/jac/dks27922833642
   PubMed Web of Science ®Google Scholar
• Institute CA, L S. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes second edition: approved standard M24-A2. CLSI. 2011 Wayne, PA, USA.
   Google Scholar
• Pandey R, et al. Dual beta-Lactam combinations highly active against Mycobacterium abscessus Complex In Vitro. mBio. 2019;10. doi:10.1128/mBio.02895-18
   Web of Science ®Google Scholar
• Lee MC, et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother. 2017;72:2782–2786. doi:10.1093/jac/dkx21229091186
   PubMed Web of Science ®Google Scholar
• Kusuki M, et al. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis. Diagn Microbiol Infect Dis. 2018;91:256–259. doi:10.1016/j.diagmicrobio.2018.02.00829550059
   PubMed Web of Science ®Google Scholar
• Ananta P, et al. Analysis of drug-susceptibility patterns and gene sequences associated with clarithromycin and amikacin resistance in serial Mycobacterium abscessus isolates from clinical specimens from Northeast Thailand. PLoS One. 2018;13:e0208053. doi:10.1371/journal.pone.020805330496270
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace R, J Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716–746. doi:10.1128/cmr.15.4.716-746.200212364376
   PubMed Web of Science ®Google Scholar
• Mougari F, et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother. 2016;71:2208–2212. doi:10.1093/jac/dkw13027147307
   PubMed Web of Science ®Google Scholar
• Li YM, et al. Prevalence and antimicrobial susceptibility of Mycobacterium abscessus in a general hospital, China. Biomed Environ Sci. 2016;29:85–90. doi:10.3967/bes2016.00927003165
   PubMed Web of Science ®Google Scholar
• Chua KY, Bustamante A, Jelfs P, Chen SC, Sintchenko V. Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales, Australia. Pathology. 2015;47:678–682. doi:10.1097/PAT.000000000000032726517625
   PubMed Web of Science ®Google Scholar
• Shen Y, et al. In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics. Biomed Res Int. 2018:4902941. doi:10.1155/2018/4902941.30687747
   PubMed Web of Science ®Google Scholar
• Aono A, et al. Antimicrobial susceptibility testing of Mycobacteroides (Mycobacterium) abscessus complex, Mycolicibacterium (Mycobacterium) fortuitum, and Mycobacteroides (Mycobacterium) chelonae. J Infect Chemother. 2019;25:117–123. doi:10.1016/j.jiac.2018.10.01030447882
   PubMed Web of Science ®Google Scholar
• Park S, et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci. 2008;23:49–52. doi:10.3346/jkms.2008.23.1.4918303198
   PubMed Web of Science ®Google Scholar
• Yoshida S, et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. Int J Antimicrob Agents. 2013;42:226–231. doi:10.1016/j.ijantimicag.2013.04.02923850022
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45:764–767. doi:10.1128/AAC.45.3.764-767.200111181357
   PubMed Web of Science ®Google Scholar
• Cowman S, Burns K, Benson S, Wilson R, Loebinger MR. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect. 2016;72:324–331. doi:10.1016/j.jinf.2015.12.00726723913
   PubMed Web of Science ®Google Scholar
• Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment outcomes of lung disease caused by mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017;64:301–308. doi:10.1093/cid/ciw72328011609
   PubMed Web of Science ®Google Scholar
• Bastian S, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother. 2011;55:775–781. doi:10.1128/AAC.00861-1021135185
   PubMed Web of Science ®Google Scholar
• Lee SH, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med. 2014;34:31–37. doi:10.3343/alm.2014.34.1.3124422193
   PubMed Web of Science ®Google Scholar
• Li B, et al. Relationship between antibiotic susceptibility and genotype in Mycobacterium abscessus clinical isolates. Front Microbiol. 2017;8:1739. doi:10.3389/fmicb.2017.0173928959242
   PubMed Web of Science ®Google Scholar
• Hanson KE, Slechta ES, Muir H, Barker AP. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? J Clin Microbiol. 2014;52:1705–1707. doi:10.1128/JCM.03464-1324554745
   PubMed Web of Science ®Google Scholar
• Kim HY, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol. 2010;54:347–353. doi:10.1111/j.1348-0421.2010.00221.x20536733
   PubMed Web of Science ®Google Scholar
• Mougari F, et al. Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.00943-16
   Web of Science ®Google Scholar
• Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL. New beta-Lactamase inhibitors nacubactam and zidebactam improve the in vitro activity of beta-Lactam antibiotics against Mycobacterium abscessus complex clinical isolates. Antimicrob Agents Chemother. 2019;63. doi:10.1128/AAC.00733-19.
   Web of Science ®Google Scholar